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Abstract
Background: It is now well established that IL-4 has a central role in the development of monocytes to multinucle-
ated giant cells (MGCs) by inducing the expression of integrins on the surface of monocytes. The aim of this study 
was to investigate the potential role of IL-4 in induction of  β5 integrin expression in the peripheral blood samples 
of patients with giant cell granuloma. 
Material and Methods: Monocytes were isolated from peripheral blood samples of patients with central giant cell 
granuloma (CGCG) and healthy controls using human Monocyte Isolation Kit II. Isolated monocytes were then 
cultured in the absence or presence of IL-4 (10 and 20 ng/mL), and following RNA extraction and cDNA synthe-
sis, Real-time PCR was performed to determine the level of β5 integrin expression. The formation of CGCGs and 
morphological analyses were done under light microscopy. For confirmation of CGCGs, immunocytochemistry 
technique was also carried out by anti-RANK (receptor-activator of NF-κB ligand) antibody. 
Results: In both patient and control groups, β5 levels were significantly enhanced by increasing the IL-4 dose from 
10 to 20 ng/mL. In addition, these differences were significant between patient and control groups without IL-4 
treatment. On the other hand, the number of cells which expressed RANK and therefore the number of giant cells 
were significantly higher in the patient group in comparison to controls, as assessed by immunohistochemistry 
evaluations. 
Conclusions: In this study, we showed an elevation in the expression levels of β5 integrin when stimulated by IL-4. 
It is strongly indicated that this integrin acts as an important mediator during macrophage to macrophage fusion 
and development of giant cells. 
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Introduction
Central giant cell granuloma (CGCG) and peripheral gi-
ant cell granuloma (PGCG) are non-neoplastic lesions 
of jaw bones typically containing many MGCs (1). 
These lesions share common histopathological features 
and usually occur in the gums as well as alveolar mu-
cosa of mandibular and maxillary bone (2,3). CGCGs 
are intraosseous non-neoplastic proliferative lesions 
and solely occur in maxillary bones (4). As to histology, 
this type of osteolytic lesions share some features with 
PGCG such as proliferation of fibrous tissue, hemosid-
erin deposits, hemorrhagic foci, reactive bone forma-
tion and osteoclast-like giant cells (5). CGCGs are more 
aggressive and typically tend to relapse. Unlike CGCG, 
PGCG is reactive, extraosseous and exophytic, settled 
in the alveolar ridge in the gingiva (6,7). Although 
these lesions were observed for the first time in 1953 
by Jaffe (8), their exact origin ‎and clear etiology are not 
well elucidated despite huge amount of research.  ‎ In the 
last few years, macrophages, osteoclast precursors and 
some osteoblastic cells have been noted in the CGCG 
and PGCG derived mononuclear cells (9). Previously, 
some studies have revealed that probably the giant cells 
of these lesions are formed from the mononuclear cells 
(10). However, the exact association between giant cells 
and mononuclear cells has not been clearly understood 
(11).
It is proposed that inflammatory-immune mechanisms 
might be behind the pathogenesis of these lesions. This 
idea was confirmed by the presence of the osteoclast-
like cells interacting with mononuclear cells (12). In 
individuals with CGCG, a change in the number of cir-
culating lymphocytes and monocytes producing anti-
inflammatory and inflammatory cytokines, including 
interleukin-3 (IL-3), IL-4, IL-10, and IL-13 is observed 
(10). IL-4 particularly, can act as a pivotal element in 
regulating the differentiation and functional activity of 
monocyte-macrophage lineage cells (13). There is now 
accumulating evidence that IL-4 can promote the forma-
tion of MGC in vitro through relatively unknown mech-
anisms (14). In one of these studies, it was shown that 
IL-4 prevents the differentiation of myeloid precursors 
to osteoclasts, which is mediated by the RANK through 
STAT6-dependent signaling pathway (15). Therefore, it 
was proposed that IL-4 might act as a molecular switch 
between osteoclasts and MGCs (16). In addition, IL-4 
can regulate the expression of E-cadherin on the cell 
surface, causing homotypic cell fusion and the forma-
tion of giant cells (13).
The integrins, a superfamily of cell adhesion molecules, 
mediate cell-cell and cell-extracellular matrix (ECM) 
interactions. These heterodimeric molecules comprise 
of α and β subunits and are important meditators of 
signal transduction between extra- and intracellular 
environments (17). Some members of β1 and β2 integ-
rins family are expressed by monocytes/macrophages. 
Therefore, it is suggested that these families are neces-
sary and sufficient directors of adhesion in monocyte-
to-macrophage development and IL-4-induced MGC 
formation (18). 
In other words, IL-4 is supposed to cause an increase 
in the expression of this specific subgroup of integrins 
and also integrin receptors, leading to advancement of 
the mentioned process. In the present study, we aimed 
to investigate the potential induction of β5 expression in 
response to IL-4 (19). β5 is a novel β subunit and pro-
motes cellular attachment to vitronectin and fibronectin 
ligands exclusively and is also involved in the morpho-
logical transformation of monocytes to giant cells.
Material and Methods
- Patients and Ethics 
Blood samples were obtained from 5 CGCG patients 
and healthy donors were also used as control. All par-
ticipants have given written informed consent and the 
study protocol was conducted in accordance with the 
Ethics Committee of Tabriz University of Medical Sci-
ences which was in compliance with the Helsinki dec-
laration.
- Monocytes Isolation 
Human blood-derived monocytes from patients with 
giant cell granuloma and controls were isolated from 
whole blood drawn from healthy individuals. Briefly, a 
1:3 blood/PBS dilution was placed over Histopaque den-
sity gradient (Histopaq-1077, Sigma-Aldrich, St. Louis, 
MO), followed by centrifugation at 500 g for 25 min. 
The interface was separated and washed three times 
with PBS. Monocytes were isolated using the human 
Monocyte Isolation Kit II (Milteny Biotec, Auburn, 
CA). Approximately 50 million cells obtained from the 
Histopaque separation were resuspended in 500 µl of 
degassed buffer (PBS without  Ca++ and Mg++ at a pH 
of 7.2 + 2 mM EDTA + 0.5% BSA), followed by the ad-
dition of 100 µl of the BiotinAntibody Cocktail and 100 
µl of FcR Blocking Reagent. The cell suspension was 
incubated at 4o C for 10 min. 250 µl of the buffer and 
250 µl Anti-Biotin Microbeads were added to the cell 
suspension. After the cells were incubated for 50 min 
at 4o C, 5 ml of the buffer was added to the cell suspen-
sion, and the cell suspension was centrifuged at 250 g 
for 12 min. Cells were resuspended in 500 µl of the buf-
fer and run through a Magnetic Separation LS column 
(Milteny Biotec). 10 ml of the buffer was added to the 
column, and the effluent 6 (monocytes) was collected. 
The monocyte suspension was centrifuged at 250 g for 
15 min, and the cell pellet was resuspended in RPMI + 
10% FCS. Monocyte purity was determined by flow cy-
tometry based on the percentage of CD14 positive cells. 
The purity was greater than 90%. 
- Cell Culture and Treatment
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Isolated monocytes were cultured in 25cm2 flasks in 
RPMI 1640 medium (Invitrogen, Life Technologies, 
Carlsbad, CA) supplemented with 15% fetal bovine se-
rum (FBS), 2 mM L-glutamine, 100 units/ml of pen-
icillin-streptomycin and then were treated with two 
different doses (10 and 20 ng/mL) of IL-4 (R & D Sys-
tems, Minneapolis, MN) for 5 days. Results represent 
the mean ± SEM of data from three different monocyte 
donors.
- RNA extraction and real-time PCR analysis 
b5 integrin and mRNA levels were quantified by qRT-
PCR. Total RNA was isolated from cells using RNeasy 
Mini Kit (Qiagen, Valencia, CA) according to the man-
ufacturer’s instructions. Complementary DNA (cDNA) 
was synthesized by cDNA synthesis kit (Qiagen) from 
1 μg of total RNA. Following on, qRT-PCR was per-
formed in the Rotor-GeneTM 6000 system (Corbett 
Life Science, Australia). The PCR reaction conditions: 
5 μL of cDNA template, 0.5 μM of each primer, 12 μL 
of SYBR green reagent and 7 μL of nuclease-free dis-
tilled water. The b5 integrin primer sequences were as 
follows: forward, 5’-GCC TAT CTC CAC GCA CAC 
TG-3’, reverse, 5’-AGA CTC CGA CCC TTC CTG 
AC-3’; and GAPDH, forward 5’-TCT AGA CGG CAG 
GTC AGG TCC ACC-3’ and reverse, 5’-CCA CCC 
ATG GCA AAT TCC ATG GCA-3’ were used as inter-
nal controls. Cycling conditions were as follows: 94°C 
for 5 min for cDNA and primer denaturing, followed by 
35 cycles at 94°C for 30 sec, 56°C for 45 sec, and 72°C 
for 60 sec. Relative b5 integrin mRNA expression was 
determined with the 2 - (ΔΔCt) method using 18S as the 
reference gene.
- MGC formation analysis
Isolated monocytes from CGCGs plated in 24-well 
plates in the absence or presence of IL-4 (10 and 20 ng/
mL). After 5 days, the plates were fixed and MGC for-
mation was observed under light microscopy (Nikon, 
Japan). Also, immunocytochemical analysis by us-
ing a biotin-streptavidin-peroxidase staining method 
(LSAB2 kit, DAKO, Carpinteria, CA) was used to mea-
sure the relative quantities of RANK protein and MGCs 
formation. RANK protein expression on the surface of 
the monocytes is an evidence for monocyte to giant cell 
development. To determine RANK, we used rabbit an-
ti-human RANK antibody at 1:2,000 dilution (Abcam, 
Cambridge, UK). Anti-RANK antibody was directed 
against the RANK’s extracellular domain. After Anti-
RANK incubation, the cells were treated with 3% H2O2 
in PBS for 10 min to inactivate endogenous peroxidase 
activity. Sequential incubations then were performed 
with biotinylated secondary antibody for 2 hrs. and 
peroxidase-conjugated streptavidin (DAKO). Staining 
was revealed with 3,3’-diaminobenzidine (DAB, Sigma 
Chemical Co., St. Louis, Mo.). The DAB areas in slides 
are brown (highlighted DAB-immunostained slides 
with the RANK antibody); the expression levels of 
RANK quantified by measuring the intensity of brown 
area by ImageJ software (National Institues of Health, 
Bethesda, Maryland, USA). Percentage for each sample 
represents the mean ± standard deviation (S.D.) of three 
independent experiments with 3 determinations.
- Statistical analysis 
All data were presented as mean±standard deviation 
(SD) of three independent experiments, and statisti-
cal analysis was performed using SPSS 16.0 software 
through t test method. Values of P less than 0.05 were 
considered statistically significant.
Results
Five days after IL-4 treatment, the expression level of 
β5 integrin was evaluated in CGCGs and healthy groups 
by Real-time PCR. The results showed that an increase 
in IL-4 dose from 10 to 20 ng/mL causes a statistically 
significant elevation in expression levels of β5 integrin 
in patient and control samples (p=0.01 and p=0.02, re-
spectively). In addition, the differences between expres-
sion levels of β5 integrin, when compared between pa-
tient and control group, were significant bghv (p= 0.03 
in the absence of IL-4, p<0.001 for samples treated with 
10 ng/mL IL-4, and p=0.001 for samples treated with 
20 ng/mL IL-4). In other words, the expression levels in 
different treated doses were higher in patients group in 
comparison with healthy controls. More interestingly, 
these differences were significant between patient and 
control groups without IL-4 treatment (Fig. 1). Exami-
nation of cultured cells by light microscopy in CGCGs 
group showed that treatment with IL-4 causes an alter-
nation in monocyte morphology toward MGC forma-
tion (Fig. 2). For evaluating the effects of IL-4 on induc-
tion of RANK expression and MGC formation, we used 
immunocytochemistry by anti-RANK antibody (Fig. 
3). RANK protein is overexpressed by neoplastic giant 
cells, promoting fusion with macrophage colony stimu-
lating factor (M-CSF) acting as a cofactor. In immuno-
cytochemistry analyses of patient samples, the numbers 
of the giant cells formed by IL-4 induction in 10 ng/
mL and 20 ng/mL IL-4 concentration were significantly 
increased as compared with those of samples without 
IL-4 (p=0.01 and p=0.00, respectively). In patient sam-
ples, in the absence of IL-4 the percentage of giant cells 
was 31%, however in samples treated with IL-4, 73% 
of cells treated with 10 ng/mL IL-4 and 90% of cells 
treated with 20 ng/mL IL-4 were giant cells (p=0.01, 
p=0.03). These amounts are lower in control samples, 
61% and 77% in 10 and 20 ng/mL of IL-4, respectively 
(Fig. 3).
Discussion
To the best of our knowledge, this is the first study 
showing the involvement of b5 integrin in the monocyte 
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to giant cell transformation and pathological identity 
of giant cell granuloma. IL-4 treatment increases the 
expression of the b5 integrin on the monocyte surface 
and induces ‎morphological changes toward MGCs in a 
dose-dependent manner. 
From the biological point of view, the most attractive 
and significant feature of giant cells is that they are ac-
tually monocyte-derived multinucleated macrophages, 
formed by macrophage to macrophages fusion. How-
ever, the precise molecular mechanism of macrophage 
fusion has not yet been elucidated. In this regard, a very 
hot research front is the well-known and interesting 
role of IL-4 in the formation of giant cells. As a result, 
there have been several studies which investigated and 
discussed this important issue. For instance, Konodo 
and co-workers (20), studied the effects of different 
monoclonal cytokines (IL-4, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), macrophage 
colony-stimulating factor (M-CSF), Interferon gamma 
(IFN-g), Tumor necrosis factor α (TNF-α) on a popula-
tion of monocytes from cord blood and adult peripheral 
blood to investigate if they can induce MGCs. They re-
ported that among these cytokines, IL-4 alone as well 
as IL-4 in combination with M-CSF and/or GM-CSF 
could increase MGC formation in both adult peripheral 
blood and cord blood culture, significantly. In another 
study, an alternative mechanism was proposed for IL-4 
mediated induction of MGC formation. In this study, 
Yu and et al. (21) showed that NF-κB signaling is also 
required for IL-4-induced MGC formation. Addition-
ally, IL-4 lead to over-expression of p105/p50 and stim-
ulated the nuclear accumulation of p50. Furthermore, 
it was shown that the over-expression of NF-κB dimer 
proteins enhances the macrophage fusion; while on the 
other hand, p100 knockdown enhanced macrophage fu-
sion. These results indicate that NF-κB pathway con-
trols macrophage fusion induced by IL-4 treatment. 
Furthermore, Moreno and et al. (13) investigated the 
mechanism by which IL-4 promotes MGC formation, 
identifying a critical role for E-cadherin in the forma-
tion of giant cells, likely by modulating homotypic fu-
sion of precursors. They found that the IL-4-induced 
production of MGCs is STAT6-dependent, based on 
the fact that precursors derived from STAT6-/- mice 
could not develop efficiently into giant cells upon treat-
ment with IL-4. In agreement with these findings, in 
our study, treatment with IL-4 induced the formation of 
the MGCs in a dose-dependent manner from monocytes 
derived from patients with giant cell granuloma. 
During the last decade, a number of studies have been 
performed to elucidate the exact molecular mechanism 
involved in homotypic macrophage-macrophage fusion. 
Based on the results of these studies, it has been suggest-
ed that specific groups of proteins mediate macrophage-
macrophage fusion. Among these protein groups, inte-
grin receptor families, particularly β1 and β2 have been 
both recognized as sufficient and essential mediators of 
adhesion during monocyte-to-macrophage alternation 
and IL-4-induced MGC formation (22). Complement 
family proteins and fibrinogen are known to be early 
adhesion ligands to the β2 integrins and, later, vitronec-
tin has been recognized as the pivotal protein adhesion 
Fig. 1. Up-regulation of β5 Integrin mRNA by IL-4. Monocytes were isolated from CGCGs 
and healthy donors were plated in 25cm2 flasks in the absence or presence of IL-4 (10 and 20 
ng/mL). Media and IL-4 were replaced every other day. After 5 days, β5 integrin mRNA levels 
were examined by Real-time-PCR and  relative mRNA expression levels were quantified by the 
2 (-ΔΔCt) method. The results represent mean±SD (n=3); * and # p<0.05.
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substrate for IL-4-induced MGC formation (18). McNal-
ly and et al. (17) designed a study to explore the under-
lying cell/substrate interactions which support optimal 
IL-4-induced macrophage fusion and MGC formation. 
They were also evaluating the potential involvement of 
integrin in these adhesion events. They demonstrated 
that β2 integrins are required for initial monocyte adhe-
sion; however, during IL-4-induced macrophage fusion 
and MGC formation, both β1 and β2 integrins are nec-
essary to mediate adhesion. Therefore, β1 and β2 inte-
grins cooperate in cell adhesion during the formation 
Fig. 2. MGC formation is dependent on IL-4 concentra-
tion. Monocytes were isolated from CGCGs and plated in 
24-well plates in the absence or presence of IL-4 (10 and 
20 ng/mL). After 5 days, the cells were fixed and MGC 
morphology and formation was observed under light mi-
croscopy (40×). (A) Absence of IL-4; (B) Cells after IL-4 
treatment (10 ng/mL), and (C) Cells after IL-4 treatment 
(20 ng/mL). 
Fig. 3. Inductive effect of IL-4 on RANK protein ex-
pression and MGC formation. Immunocytochemistry 
results using anti-RANK Abs in monocytes isolated 
from CGCGs and plated in 24-well plates in the absence 
or presence of IL-4 (10 and 20 ng/mL). After 5 days, 
the cells were stained with DAB. (A) Absence of IL-4; 
(B) Cells after IL-4 treatment (10 ng/mL), and (C) Cells 
after IL-4 treatment (20 ng/mL). The intensity of DAB 
staining (brown stain) shows the RANK protein expres-
sion levels.
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of MGCs. On the other hand, another study revealed 
that fusing macrophages and foreign body giant cells 
(FBGCs) express an explicit group of adhesion recep-
tors, namely aX and aM of the β2 integrin, and a2, a3, 
a5, and aV of the β1 integrin subfamily. This expression 
pattern indicated that the acquisition of fusion capabili-
ties by macrophages during the formation of giant cells 
happens in parallel with the selective expression of spe-
cific adhesion molecules which might have the potential 
to interact with blood and ECM proteins (23,24). There-
fore, since integrins play such important roles in the 
MGC formation, we investigated the expression levels 
of β5 integrin after treatment with IL-4. Similar to other 
integrins, β5 integrin was over-expressed on the surface 
of the monocytes upon IL-4 treatment.
In conclusion, IL-4 induced elevation of β5 integrin 
expression, as shown by real-time PCR and immuno-
cytochemistry, indicates that β5 integrin can play a key 
role in mediating the macrophage to macrophage fusion 
and development of the giant cells in central giant cell 
granuloma. Therefore, this study and further future in-
vestigations will help to decipher of clear mechanisms 
underlying MGC formation. Subsequently, this will 
help us to come up with possible therapeutic targets for 
treatment of the central giant cell granuloma. One limi-
tation of the study was that due to the ethical issues the 
least required amount of blood was collected from the 
subjects, therefore the experiments were not repeated 
several times to achieve more accurate mean values.
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